Exelixis EXEL Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Exelixis in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The official record: Exelixis’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Exelixis's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Exelixis's cash & equivalents?
- Exelixis (EXEL) reported cash & equivalents of $226.15M in Q1 2026.
- How has Exelixis's cash & equivalents changed year-over-year?
- Exelixis's cash & equivalents increased by 23.1% year-over-year, from $183.75M to $226.15M.
- What is the long-term trend for Exelixis's cash & equivalents?
- Over 5 years (2020 to 2025), Exelixis's cash & equivalents has grown at a 8.5% compound annual growth rate (CAGR), from $320.77M to $482.49M.
- What does cash & equivalents mean?
- The total amount of cash and highly liquid short-term investments the company holds.
- How do you interpret cash & equivalents?
- An increase suggests strong liquidity and capacity for investment, while a decrease may indicate high cash burn or significant capital allocation.
- How does cash & equivalents compare across companies?
- Standard across all industries; peers in biotech typically maintain high cash balances to fund long-term clinical development.